Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD1 | P49961 | 3/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.66 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.65 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.65 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.65 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.65 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079811 | 1.00 | ENTPD1 (0.73) | ENTPD1TRPM2P2RY1SRCP2RY2 | |
| SCHEMBL15082696 | 1.00 | ENTPD1 (0.73) | ENTPD1TRPM2P2RY1SRCP2RY2 | |
| SCHEMBL374912 | 1.00 | ENTPD1 (0.73) | ENTPD1TRPM2P2RY1SRCP2RY2 | |
| SCHEMBL4314233 | 0.99 | ENTPD1 (0.72) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL8628979 | 0.95 | ENTPD1 (0.66) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL6764984 | 0.92 | SIRT2 (0.72) | ENTPD1TRPM2P2RY1SRCP2RY2 | |
| SCHEMBL4315602 | 0.92 | SIRT2 (0.72) | ENTPD1TRPM2P2RY1SRCP2RY2 | |
| SCHEMBL30583439 | 0.92 | SIRT2 (0.72) | ENTPD1TRPM2P2RY1SRCP2RY2 | |
| SCHEMBL636535 | 0.91 | ENTPD1 (0.75) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL636536 | 0.91 | ENTPD1 (0.75) | ENTPD1TRPM2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| CN-112236438-B | Phosphorus (V) based reagent, method for the production thereof, and use thereof for producing stereoregular organic phosphorus (V) compounds | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | disclosed |
| US-12077558-B2 | Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-03 | — | — | US | disclosed |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-20230212204-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-07-06 | — | — | US | disclosed |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-28 | — | — | US | disclosed |
| CN-115244061-A | Reagents and their use for modular enantioselective synthesis of C-P bonds | 百时美施贵宝公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-3774824-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112236438-A | Novel phosphorus (V) -based reagents, method for the production thereof, and use thereof for producing sterically defined organic phosphorus (V) compounds | 百时美施贵宝公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20040132067-A1 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SOMALOGIC, INC. | 2004-07-08 | — | — | US | disclosed |
| US-6482594-B2 | Made by exposing nucleic acid candidate sequences having photoreactive groups to the target molecule, irradiating complexes formed to crosslink, and separating the crosslinked complexes and amplifying to give the ligands | SOMALOGIC, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020106652-A1 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SOMALOGIC, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6291184-B1 | DETECTING TARGET MOLECULES IN A BIOLOGICAL SUBSTANCE ASSOCIATED WITH DISEASES BY EXPOSING SUBSTANCE TO A NUCLEIC ACID LIGAND THAT PHOTOCROSSLINKS TO A TARGET MOLECULE; IRRADIATING THE SUBSTANCE CONTAINING LIGAND, DETECT COMPLEXES | SOMALOGIC, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6001577-A | SCREENING FOR LIGANDS ASSOCIATED WITH A DISEASE BY DETECTING LIGAND THAT PHOTOCROSSLINKS TO TARGET WITH PHOTOREACTIVE GROUPS FROM CANDIDATE MIXTURE, REMOVING ANY NUCLEIC ACIDS WITH AFFINITIES NOT ASSOCIATED WITH DISEASE, AND AMPLIFYING | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0736105-A4 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIV RESEARCH CORP (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5763177-A | SELEX IS AN ACRONYM FOR SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; USEFUL FOR DIAGNOSIS AND/OR TREATMENT OF DISEASES OR PATHOLOGICAL OR TOXIC STATES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5620676-A | ADENOSINE TRIPHOSPHATE DERIVATIVES; TREATMENT OF SEPTIC SHOCK OR BRAIN SEIZURES, LEARNING ENHANCEMENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0736105-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995008003-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIVERSITY RESEARCH CORPORATION (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | ENTPD1 149/4885TRPM2 4743/4885P2RY1 797/4885 |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | ENTPD1 1065/4885TRPM2 3697/4885P2RY1 799/4885 |
| US-12077558-B2 | Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compounds | PPIP5K2, PLCB3, PLCG2 | ENTPD1 697/4885TRPM2 3921/4885P2RY1 402/4885 |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | PPIP5K2, INPP5B, PTMS | ENTPD1 1065/4885TRPM2 3697/4885P2RY1 799/4885 |
| US-20230212204-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | PNKP, POLL, RNGTT | ENTPD1 517/4885TRPM2 4852/4885P2RY1 1743/4885 |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | PNKP, POLL, RNGTT | ENTPD1 530/4885TRPM2 4847/4885P2RY1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.